The Day the Peptide
Rules Changed

On February 27, 2026, on a recording of The Joe Rogan Experience, United States Department of Health and Human Services Secretary Robert F. Kennedy Jr. said that within a couple of weeks the FDA would begin reversing two years of compounding restrictions on a class of widely used peptides. The promise landed in the Federal Register on April 15, 2026, and took effect a week later, on April 22.

The next major milestone is a Pharmacy Compounding Advisory Committee meeting on July 23, 2026, with a second session on July 24 and a follow-up scheduled before the end of February 2027.

This is the most consequential regulatory shift in peptide medicine in a decade. Here is what the original 2023 restrictions did, what the April 15 action formalized, which fourteen peptides are expected to return to legal compounding, and which five are not.

What the 2023 restrictions actually did

In late 2023, the FDA placed nineteen peptides on what is informally known as the Category 2 list. The category designates substances that the agency has flagged as presenting safety concerns for compounding under section 503A. In practice, being placed on Category 2 means a 503A pharmacy cannot legally compound the peptide for an individual patient, even with a prescription, until the FDA completes its review.

The list included peptides that had become widely used in clinical practice for tissue repair, growth hormone signaling, immune modulation, and cellular longevity research. BPC-157, TB-500, Selank, Semax, MOTS-c, Epitalon, GHK-Cu in injectable form, and a number of others were among them. For two years, the only legal way to access most of these molecules was through clinical trials or through international gray-market sources, with all the safety questions those routes raise.

What February 27 actually said

Kennedy's announcement on the Rogan podcast was a policy signal, not a legal action. It directed the FDA to begin moving the majority of the Category 2 peptides off the restricted list. The mechanical work of doing so happened through a different procedural route: the original entities that had nominated each peptide for Category 2 designation voluntarily withdrew those nominations.

That withdrawal sequence resolved on April 15, 2026, when the FDA published the formal removal in the Federal Register. The removal of twelve peptides from Category 2 took effect seven days later, on April 22, 2026. Combined with five peptides whose nominations had been withdrawn earlier, in September 2024, fourteen peptides have now exited Category 2 status. Five remain on the restricted list, primarily because of safety concerns, misuse potential, or proximity to existing FDA-approved drug categories.

Removal is not approval, yet

Removal from Category 2 is not the same as Category 1 status. It means the FDA is no longer flagging the substance as a safety concern, but each peptide still requires individual evaluation by the Pharmacy Compounding Advisory Committee, the standing FDA body that determines what substances may be added to the 503A bulks list. PCAC review is the technical foundation on which compounding eligibility decisions rest.

The first review meeting is scheduled for July 23 and 24, 2026. A second is expected before the end of February 2027. Together, those two sessions will determine the order and timeline for each peptide's return to active 503A compounding.

The fourteen peptides expected to return

Across the September 2024 withdrawals and the April 15, 2026 removal, fourteen peptides are expected to clear PCAC review and ultimately reach Category 1 status. They span seven therapeutic areas.

What happens next

Removal from Category 2 is the first procedural step. The full path from restricted substance to a vial in your refrigerator runs through several more.

For most of the fourteen peptides, the most likely timeline for the first additions to begin reaching pharmacies is the second half of 2026 and through 2027. The exact order will be set by the PCAC sessions.

What this means for patients

For patients waiting on these peptides, the practical effect right now is patience. Nothing has yet returned to a pharmacy near you. The legal path back is now defined and active. The first prescriptions of formerly restricted peptides will be filled when each peptide completes its formal reclassification, likely beginning in the second half of 2026.

For the broader peptide market, the February announcement and the April 15 Federal Register notice together mark the end of the post-2023 restriction era. The next chapter is one in which more peptides are legally available, prescribed by physicians, compounded by licensed pharmacies, and accompanied by the documentation patients should expect from prescription medicine.

Where pru sits in this

At pru, our protocols for the peptides expected to return have been built and ready for thirty days post-Federal Register notice. As each peptide completes its reclassification, it will be added to the pru formulary on the same terms as every other therapy: prescribed by a licensed clinician, compounded at a state-licensed 503A pharmacy, and accompanied by a Certificate of Analysis on every batch. The science and the regulatory framework are converging. The transparency we have built around peptide therapy will scale with them.